Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.

Autor:	Zhou S; Lineberger Comprehensive Cancer Center.; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill., Long N; Lineberger Comprehensive Cancer Center., Rosenke K; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Jarvis MA; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.; School of Biomedical Sciences, University of Plymouth.; The Vaccine Group Ltd, Plymouth, Devon, United Kingdom., Feldmann H; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana., Swanstrom R; Lineberger Comprehensive Cancer Center.; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Dec 16; Vol. 230 (6), pp. 1380-1383.
DOI:	10.1093/infdis/jiae213
Abstrakt:	We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir. Competing Interests: Potential conflicts of interest. The University of North Carolina is pursuing intellectual property protection for Primer ID and R. S. has received nominal royalties. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.Elements of the work have been written by employees of the US Government.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu